Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

Nov 15 (Reuters) - The US Food and Drug Administration on Sunday declined to approve Summit ​Therapeutics' lung cancer drug ‌ivonescimab, a setback for efforts to expand treatment for patients whose cancer has progressed after earlier therapies. In its...

Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

Complete Response Letter Received from FDA for BLA Application Based on HARMONi Study

FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting

The FDA rejected a new cancer treatment from Summit Therapeutics and Akeso in a decision that analysts largely expected, but ultimately shouldn’t dim the prospects for a promising class of drugs. Regulators turned down ivonescimab ...